Publicacións en colaboración con investigadores/as de Universidade da Coruña (8)

2022

  1. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer? (Virchows Archiv, (2021), 479, 4, (853-857), 10.1007/s00428-021-03104-7)

    Virchows Archiv

  2. Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?

    Virchows Archiv, Vol. 479, Núm. 4, pp. 853-857

  3. PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: Summary of an expert round-table discussion

    Future Oncology, Vol. 17, Núm. 10, pp. 1209-1218

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170

  2. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: Efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

    Breast Cancer: Targets and Therapy, Vol. 11, pp. 29-42

2015

  1. IL-36α: A novel cytokine involved in the catabolic and inflammatory response in chondrocytes

    Scientific Reports, Vol. 5

2010

  1. Gingival mucinous adenocarcinoma of a minor salivary gland

    Journal of Periodontology, Vol. 81, Núm. 4, pp. 626-631